Stockpolly
Search
TBPH · NASDAQ · Biotechnology

Theravance Biopharma (TBPH)

Commercializes YUPELRI with Viatris while winding down ampreloxetine.

$17.08
At close+0.05 (+0.29%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue161815141719152620461821
Cost of revenue189109911108201
Gross profit149648941612441819
231517201819181818272420
Research & development899109911108765
151600019000201814
Selling & marketing050004000000
General & administrative011000140000014
Other expenses0−98109−97810001
Operating income−9−6−11−16−11−9−14−3−618−6−1
111010076456−1−4
Interest income221111114033
Interest expense111111111100
Other non-operating income−20−1−3−2−1−1−77−4−5610
Income before tax−8−5−10−15−10−9−1473−373−6−5
Income tax expense131137−118−712−21
Net income from continuing operations−9−9−12−17−13−16−1455461−5−6
Net income−9−9−12−17−13−16−1455461−5−6
EPS, basic−$0.17−$0.17−$0.24−$0.34−$0.26−$0.31−$0.27$1.09$0.07$1.20−$0.10−$0.11
EPS, diluted−$0.17−$0.17−$0.24−$0.34−$0.26−$0.31−$0.27$1.08$0.07$1.15−$0.10−$0.11
Weighted average shares, basic524948494949505051515152
Weighted average shares, diluted524948494949505152535152
EBITDA−6−6−9−12−9−8−1374−275−61
Depreciation & amortization100001000211
EBIT−7−7−10−13−9−8−1374−274−6−1